F S&P 500
5,210.50 -2.25 (-0.04%) F Dow Jones
39,197.00 +2.00 (+0.01%) F Nasdaq
18,170.25 -16.25 (-0.09%) E-mini Russell 2000 Index Futur
2,062.80 -2.00 (-0.10%) Petróleo
79.32 +0.33 (+0.42%) Oro
2,316.80 -5.50 (-0.24%)
Biomea Fusion, Inc. (BMEA)
Fuera de horario:
Biomea Fusion, Inc.
900 Middlefield Road
4th Floor
Redwood City, CA 94063
United States
650 980 9099
https://biomeafusion.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 110
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Thomas Andrew Butler | Co-Founder, Chairman & CEO | 950.41k | N/D | 1981 |
| Mr. Ramses M. Erdtmann | Co-Founder, President, COO & Director | N/D | N/D | 1963 |
| Mr. Franco Valle | CFO & Principal Accounting Officer | 673.66k | N/D | 1981 |
| Dr. Juan Pablo Frias M.D. | Chief Medical Officer | 492.25k | N/D | N/D |
| Mr. Heow Tan | Chief Technology & Quality Officer | N/D | N/D | 1959 |
| Ms. Naomi Cretcher | Chief People Officer | N/D | N/D | N/D |
| Dr. Thorsten Kirschberg Ph.D. | Executive Vice President of Chemistry | N/D | N/D | 1970 |
| Dr. Stephan Morris M.D. | Chief Development Officer | N/D | N/D | N/D |
| Mr. Ravi Upasani | Executive Vice President of Intellectual Property | N/D | N/D | N/D |
| Caroline Perez- Dupont | Senior Vice President of Contracts | N/D | N/D | N/D |
Descripción
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Biomea Fusion, Inc. a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 6; Junta: 9; Derechos del accionista: 8; Compensación: 9.
